Mesenchymal-epithelial transition factor amplification correlates with adverse pathological features and poor...

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Colorectal cancer (CRC) is a leading cause of cancer mortality globally.
• The MET gene plays a role in tumor biology and is a potential therapeutic target.
• Limited data exist on MET amplification in CRC, necessitating further investigation.

Purpose of the Study:

• To investigate the pathological significance of MET amplification in colorectal cancer.
• To evaluate MET amplification as a prognostic marker in CRC.
• To propose a feasible screening strategy for MET amplification in CRC.

Main Methods:

• Analysis of 205 newly diagnosed CRC patients without prior therapy.
• Assessment of MET amplification using fluorescence in situ hybridization (FISH).
• Evaluation of c-MET protein expression via immunohistochemistry (IHC).
• Correlation analysis of MET aberration with pathological features and survival outcomes (PFS).

Main Results:

• Polysomy-induced MET amplification detected in 14.4% of CRC cases; focal amplification was rare.
• MET amplification correlated with increased lymph node metastasis and higher tumor budding grade.
• Patients with MET amplification showed significantly poorer two-year progression-free survival (PFS).
• IHC showed variable c-MET expression but poor correlation with MET amplification status.

Conclusions:

• Focal MET amplification is uncommon in CRC.
• Polysomy-induced MET amplification is associated with adverse pathological features and poor prognosis in CRC.
• IHC is not a suitable method for screening MET amplification in CRC.